Switch From rhPTH1-84 to TransCon PTH With Individual Dose Adjustment in Adult Hypoparathyroidism-4-Week Results.

Siggelkow H, Peschke KA, Tsourdi E, Hofbauer LC, Berr CM, Hahner S, Lottspeich C, Schmidmaier R, Blaschke M

Journal of the Endocrine Society30 Jun 2025Cited by 1 (Europe PMC)

PMID40709359PMCIDPMC12287600DOI10.1210/jendso/bvaf113PepBankPUB-40709359

Summary

BackgroundReplacement therapy with recombinant human PTH (rhPTH1-84) represents a causal treatment for patients with chronic hypoparathyroidism (HypoPT). Recently, palopegteriparatide (TransCon PTH), a novel long-acting drug with slow release of PTH1-34, was approved by the European Medicines Agency and Food and Drug Administration for treatment of HypoPT. To date, no data exist on the treatment switch from rhPTH1-84 to TransCon PTH.MethodsWe retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.ResultsWithin the first month after the treatment switch, 80% (n = 32) of patients needed individual adjustment of their TransCon PTH dose to achieve normocalcemia. Dose reduction (to 9-15 µg) was necessary in 38% (n = 15) and an increase (to 21-27 µg) in 43% (n = 17) of patients. Adjustments occurred predominantly (in 62% cases) according to serum calcium levels, partly dependent on symptoms. The prior applied rhPTH1-84 dose correlated significantly with the adjusted TransCon PTH dose (r = 0.4; P = .01). The treatment change was associated with moderate or mild adverse events in 24/40 patients.ConclusionWe hereby report the first clinical data on switching treatment from rhPTH1-84 to 18 µg TransCon PTH independent of the prior rhPTH1-84 dose. Our data support discrete adaptation of the starting dose depending on the prior rhPTH1-84 dosage.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyOther
In patients switching to TransCon PTH, 80% (n = 32) required dose adjustment within the first month to achieve normocalcemia.
In plain wordsIn patients switching to TransCon PTH, 80% required dose adjustment within the first month to achieve normal calcium.
Peptide
Palopegteriparatide
Outcome
Not applicableIndividual dose adjustment
Study
n = 40
Outcome group
Dose requirements · Endocrine and hormones
Studied dose
initially 18 µg, individually adjustedAs given in this study (human).
Measurements
Patients needing individual dose adjustment
80%
first month after switch
Patients needing individual dose adjustment
32 patients
first month after switch
Source sentences
Summary
Within the first month after the treatment switch, 80% (n = 32) of patients needed individual adjustment of their TransCon PTH dose to achieve normocalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.
Show in the study text Report a problemFND-4070935901
02HumanObservational studyOther
In patients switching to TransCon PTH, 38% (n = 15) needed dose reduction to 9-15 µg.
In plain wordsIn patients switching to TransCon PTH, 38% needed dose reduction to 9-15 µg.
Peptide
Palopegteriparatide
Outcome
DecreaseDose reduction
Study
n = 40
Outcome group
Dose requirements · Endocrine and hormones
Studied dose
initially 18 µg, individually adjustedAs given in this study (human).
Measurements
Patients needing dose reduction
38%
after switch
Patients needing dose reduction
15 patients
after switch
Reduced TransCon PTH dose
9 to 15 µg
patients with dose reduction
Source sentences
Summary
Dose reduction (to 9-15 µg) was necessary in 38% (n = 15) and an increase (to 21-27 µg) in 43% (n = 17) of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.
Show in the study text Report a problemFND-4070935902
03HumanObservational studyOther
In patients switching to TransCon PTH, 43% (n = 17) needed dose increase to 21-27 µg.
In plain wordsIn patients switching to TransCon PTH, 43% needed dose increase to 21-27 µg.
Peptide
Palopegteriparatide
Outcome
IncreaseDose increase
Study
n = 40
Outcome group
Dose requirements · Endocrine and hormones
Studied dose
initially 18 µg, individually adjustedAs given in this study (human).
Measurements
Patients needing dose increase
43%
after switch
Patients needing dose increase
17 patients
after switch
Increased TransCon PTH dose
21 to 27 µg
patients with dose increase
Source sentences
Summary
Dose reduction (to 9-15 µg) was necessary in 38% (n = 15) and an increase (to 21-27 µg) in 43% (n = 17) of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.
Show in the study text Report a problemFND-4070935903
04HumanObservational studyOther
In patients switching to TransCon PTH, prior rhPTH1-84 dose correlated positively with adjusted TransCon PTH dose (r = 0.4; P = .01).
In plain wordsIn patients switching to TransCon PTH, higher prior rhPTH1-84 doses were linked to higher adjusted TransCon PTH doses.
Peptide
Palopegteriparatide
Outcome
IncreasePrior rhPTH1-84 dose correlation with adjusted dose
Study
n = 40
Outcome group
Dose requirements · Endocrine and hormones
Studied dose
initially 18 µg, individually adjustedAs given in this study (human).
Measurements
Correlation of prior rhPTH1-84 dose with adjusted TransCon PTH dose (r)
0.4
retrospective cohort
P value
0.01
correlation
Source sentences
Summary
The prior applied rhPTH1-84 dose correlated significantly with the adjusted TransCon PTH dose (r = 0.4; P = .01).
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.
Show in the study text Report a problemFND-4070935905
05HumanObservational studySafety outcome
In patients switching to TransCon PTH, the treatment change was linked to mild or moderate adverse events in 24/40 patients.
In plain wordsIn patients switching to TransCon PTH, the treatment change was linked to mild or moderate adverse events in 24/40 patients.
Peptide
Palopegteriparatide
Outcome
Not applicableMild or moderate adverse events
Study
n = 40
Outcome group
Adverse events · Whole body
Studied dose
initially 18 µg, individually adjustedAs given in this study (human).
Measurements
Patients with mild or moderate adverse events
24 patients
of 40 patients after treatment change
Source sentences
Summary
The treatment change was associated with moderate or mild adverse events in 24/40 patients.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.
Show in the study text Report a problemFND-4070935906
06HumanObservational studyOther
In patients switching to TransCon PTH, 62% of adjustments followed serum calcium levels and partly symptoms.
In plain wordsIn patients switching to TransCon PTH, 62% of adjustments followed serum calcium levels and partly symptoms.
Peptide
Palopegteriparatide
Outcome
Not applicableSerum calcium-guided dose adjustments
Study
n: not reported in source
Outcome group
Dose requirements · Endocrine and hormones
Studied dose
initially 18 µg, individually adjustedAs given in this study (human).
Measurements
Adjustments made according to serum calcium
62%
dose adjustments
Source sentences
Summary
Adjustments occurred predominantly (in 62% cases) according to serum calcium levels, partly dependent on symptoms.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18 µg of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.
Show in the study text Report a problemFND-4070935904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT07299838

Palopegteriparatide in Chronic Hypoparathyroidism

National and Kapodistrian University of Athensn = 901 Jun 2024 to 23 Oct 2025

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 26 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.